Centogene's ground-breaking family genetic research published in the new england journal of medicine reveals path to potential cure for structural birth defects

Cambridge, mass. and rostock, germany and berlin, sept. 29, 2021 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today the publication of results from a ground-breaking global genetic study in the new england journal of medicine (http://www.nejm.org/doi/full/10.1056/nejmoa2033911), including findings of a potential treatment of structural birth defects caused by specific gene alterations.
CNTG Ratings Summary
CNTG Quant Ranking